GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grand Pharmaceutical Group Ltd (FRA:MX6A) » Definitions » Cash Ratio

Grand Pharmaceutical Group (FRA:MX6A) Cash Ratio : 0.48 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Grand Pharmaceutical Group Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Grand Pharmaceutical Group's Cash Ratio for the quarter that ended in Dec. 2024 was 0.48.

Grand Pharmaceutical Group has a Cash Ratio of 0.48. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Grand Pharmaceutical Group's Cash Ratio or its related term are showing as below:

FRA:MX6A' s Cash Ratio Range Over the Past 10 Years
Min: 0.16   Med: 0.35   Max: 0.55
Current: 0.48

During the past 13 years, Grand Pharmaceutical Group's highest Cash Ratio was 0.55. The lowest was 0.16. And the median was 0.35.

FRA:MX6A's Cash Ratio is ranked worse than
56.35% of 992 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs FRA:MX6A: 0.48

Grand Pharmaceutical Group Cash Ratio Historical Data

The historical data trend for Grand Pharmaceutical Group's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grand Pharmaceutical Group Cash Ratio Chart

Grand Pharmaceutical Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.55 0.51 0.38 0.43 0.48

Grand Pharmaceutical Group Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.34 0.43 0.36 0.48

Competitive Comparison of Grand Pharmaceutical Group's Cash Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grand Pharmaceutical Group's Cash Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Grand Pharmaceutical Group's Cash Ratio falls into.


;
;

Grand Pharmaceutical Group Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Grand Pharmaceutical Group's Cash Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash Ratio (A: Dec. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=385.88/807.552
=0.48

Grand Pharmaceutical Group's Cash Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash Ratio (Q: Dec. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=385.88/807.552
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Grand Pharmaceutical Group  (FRA:MX6A) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Grand Pharmaceutical Group Cash Ratio Related Terms

Thank you for viewing the detailed overview of Grand Pharmaceutical Group's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Grand Pharmaceutical Group Business Description

Traded in Other Exchanges
Address
99 Queen's Road, Units 3302, 33rd Floor, The Center, Central, Hong Kong, HKG
Grand Pharmaceutical Group Ltd, is an international pharmaceutical company of technological innovation. Its core businesses cover three areas: nuclear medicine anti-tumor diagnosis and treatment, cerebro-cardiovascular precision interventional diagnosis and treatment technology, pharmaceutical technology, and biotechnology. Based on the pharmaceutical and biological industries, the Group focuses on the needs of patients, and technological innovation as the driving force Geographically, it derives a majority of its revenue from the PRC and also has a presence in America; Europe; and Asia other than the PRC, and others.

Grand Pharmaceutical Group Headlines

No Headlines